A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness

George Christodoulakos, George E Christodoulakos, D. Botsis, Dimitrios S Botsis, Irene V Lambrinoudaki, Ιrene Lambrinoudaki, V. Papagianni, Vasiliki D Papagianni, Constantinos Panoulis, Constantinos P Panoulis, Maria G Creatsa, Maria Creatsa, Andreas Alexandrou, Andreas P Alexandrou, Areti D Augoulea, Areti Augoulea, Spyros Dendrinos, Spyros G Dendrinos, George Creatsas, George C Creatsas
Maturitas · 2005 · vol. 53(4) , pp. 413–423 · doi:10.1016/j.maturitas.2005.07.003 · PMID:16140483 · W1971185391
Other OA: closed CC0 ⤵ 10 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This 5-year study investigated the effects of hormone therapy, tibolone, and raloxifene on vaginal bleeding and endometrial thickness in postmenopausal women.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVES: To study the effect of standard and low-dose estrogen-progestin therapy (EPT), tibolone and raloxifene on the incidence of vaginal spotting/bleeding and endometrial thickness over a 5-year period. METHODS: Seven hundred eighty-six postmenopausal women were studied in an open prospective design. Vaginal spotting/bleeding and endometrial thickness as assessed by transvaginal ultrasonography was compared between six categories of women over a 5-year period: three categories in women on continuous combined estrogen-progestin therapy, one category under tibolone, one category under raloxifene and one under no treatment. More specifically, women received tibolone 2.5 mg (N = 204), raloxifene HCl 60 mg (N = 137), conjugated equine estrogens 0.625 mg/medroxyprogesterone acetate 5mg (N = 122), 17beta-estradiol 2mg/norethisterone acetate 1mg (N = 58), 17beta-estradiol 1mg/norethisterone acetate 0.5mg (N = 76) or no therapy (controls, N = 189). Women with suspected endometrial pathology were referred for hysteroscopy. RESULTS: Bleeding/spotting incidence was highest among standard dose EPT users (conjugated equine estrogens 0.625 mg/medroxyprogesterone acetate 5mg: 40.1%, 17beta-estradiol 2mg/norethisterone acetate 1mg: 44.8%, p < 0.001 compared to controls). Low-dose EPT associated with lower incidence of spotting/bleeding (34.1%). The incidence under tibolone and raloxifene was 22.5% and 2.9%, respectively, while 3.2% of women not receiving therapy reported vaginal spotting/bleeding. Mean endometrial thickness was not significantly affected in any of the groups studied. The drop-out rate due to spotting/bleeding was higher in the two higher dose EPT regimens. After logistic regression analysis, age at baseline was the only significant predictor of subsequent spotting/bleeding (b = -0.25, S.E. = 0.09, p = 0.006), while menopausal age and pre-treatment serum FSH had marginal significance. CONCLUSIONS: EPT, tibolone and raloxifene do not appear to associate with significant changes in endometrial thickness in the majority of cases. The low-dose EPT regimen associated with a decreased incidence of unscheduled spotting/bleeding compared to the standard dose regimens. Tibolone expressed a favorable endometrial profile, as seen in its effect on unscheduled spotting/bleeding and mean endometrial thickness. Raloxifene associated with the lowest incidence in S/B and the lowest drop-out rate.s.

My notes (saved in your browser only)

MeSH descriptors

Endometrium Estrogen Receptor Modulators Estrogen Replacement Therapy Metrorrhagia Norpregnenes Raloxifene Hydrochloride Aged Endometrium Estrogen Receptor Modulators Estrogen Receptor Modulators Estrogen Replacement Therapy Estrogen Replacement Therapy Female Follicle Stimulating Hormone Follicle Stimulating Hormone Humans Metrorrhagia Middle Aged Norpregnenes Norpregnenes

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (71)

Cited by (10)

Source provenance

openalex
last seen: 2026-05-11T06:21:44.532445+00:00
pubmed
last seen: 2026-10-08T21:03:18.265172+00:00
unpaywall
last seen: 2026-10-16T06:24:35.758740+00:00
License: CC0 · commercial use OK